PeakLifeRx is a 503B procurement platform — semaglutide availability changed in 2025
PeakLifeRx is a technology-enabled procurement platform connecting clinics to FDA-registered 503B outsourcing facilities. All GLP-1 products it lists come from 503B outsourcing facilities under cGMP standards — not patient-specific 503A compounders. After FDA removed semaglutide from the shortage list in early 2025, 503B outsourcing facilities generally lost the shortage-list authority to compound semaglutide for clinic stock. Whether PeakLifeRx's current 503B network still compounds semaglutide and under what FDA pathway is not confirmed on peakliferx.com — ask directly before designing a program around the assumption.
This is the most important supply question for any GLP-1 clinic evaluating PeakLifeRx in 2025 or later. Fizy Health routes patient-specific semaglutide prescriptions to LegitScript-certified 503A partners, where the per-patient prescription model is unaffected by 503B office-use bulk restrictions. Per-vial 503A cost shows on each catalog and cart line before checkout, the whole refill day goes into one validated clinic cart, and steady patients can move to auto-ship so a titration program keeps shipping on schedule.